Janssen cleared to market Invokamet XR
Janssen Pharmaceuticals Inc. has received approval from the Food and Drug Administration for Invokamet XR, a type 2 diabetes medication.
Supplier News
PhRMA gathers scientists on Capitol Hill
The Pharmaceutical Research and Manufacturers of America (PhRMA) yesterday brought more than 60 researchers and scientists from its member companies to meet with congressional lawmakers.
KVK Tech weight-loss drug Lomaira approved
KVK Tech Inc. plans to release Lomaira tablets, a short-term, low-dose prescription medicine for weight loss, by the end of this month. KVK said Tuesday that Lomaira (phentermine hydrochloride 8-mg tablets CIV) gained approval from the Food and Drug Administration.
Oxy Bump oxygen-infused sprays roll out to CVS
Oxy Bump Corp. has landed retail distribution for its line of oxygen-infused nasal congestion, allergy relief and sore throat relief sprays at CVS Pharmacy.
Allergan announces pair of biopharma acquisitions
Chalk up three acquisitions for Allergan plc in less than a week. On Tuesday, Allergan said it plans to purchase clinical-stage biopharmaceutical company Tobira Therapeutics Inc. in an agreement valued at up to $1.695 billion.
U by Kotex expands Security Ultra Thin pad line
U by Kotex has rolled out two new products, Security Ultra Thin Pads Long and Security Ultra Thin Overnight Pads. The Kimberly-Clark feminine care brand said Tuesday that its latest offerings expand its line of “unique, colorful and bold” products to fit women’s “period needs.
GlaxoSmithKline tabs consumer health chief as CEO
Emma Walmsley has been named to succeed Sir Andrew Witty as chief executive officer of GlaxoSmithKline plc. The drug maker said Tuesday that Walmsley, CEO of GSK Consumer Healthcare, is slated to take the reins from Witty when he retires on March 31, 2017. Plans call for her to become a member of
Unilever strikes deal to buy Seventh Generation
Consumer products giant Unilever plans to acquire eco-friendly household and personal care products maker Seventh Generation Inc. Financial terms of the agreement weren’t disclosed. Unilever said completion transaction is pending regulatory approvals. Unilever described Burlington, Vt.
Amneal set to release Yuvafem
Amneal Pharmaceuticals LLC next month plans to begin shipping Yuvafem 10-mcg estradiol vaginal inserts, a treatment for menopausal symptoms. Amneal said Monday that its product represents the first generic equivalent of Vagifem from Novo Nordisk.
Allergan to acquire Vitae Pharmaceuticals
Allergan plc plans to buy clinical-stage biotech firm Vitae Pharmaceuticals Inc. in a cash deal valued at $639 million.
SheaMoisture takes on divisive beauty standards
SheaMoisture manufacturer Sundial Brands has launched the second phase of its #BreakTheWalls platform highlighting divisive constructs of beauty.
WellDoc, LifeScan team on type 2 diabetes digital solution
Health technology provider WellDoc has entered a commercial partnership with LifeScan Inc., a unit of Johnson & Johnson Diabetes Care Cos., to deliver a digital health solution for type 2 diabetes nationwide.
Glenmark cleared to market Xylocaine generic
Glenmark Pharmaceuticals Inc. USA has received final approval from the Food and Drug Administration for lidocaine ointment 5%. Glemark said its product is a generic version of Xylocaine ointment 5% from AstraZeneca.
Amneal adds to women’s health lineup
Amneal Pharmaceuticals LLC has expanded its portfolio of women’s health products with the release of Femynor, a birth control pill. Amneal said Femynor (norgestimate and ethinyl estradiol tablets, 0.25 mg/0.
Upsher-Smith rolls out Qudexy XR savings program
Upsher-Smith Laboratories Inc. has launched a new savings and support program for Qudexy XR extended-release capsules, a once-daily, broad-spectrum anti-epileptic medication.
Revlon closes Elizabeth Arden acquisition
Revlon Inc. has completed its acquisition of fellow beauty care company Elizabeth Arden. Revlon said late Wednesday that the closing of the transaction, announced in mid-June and valued at about $870 million, came after Elizabeth Arden’s shareholders approved the deal in a vote earlier in the day.